Financings Of The Fortnight Sees More Conflicting Indicators For Biotech VC
This article was originally published in The Pink Sheet Daily
Quarterly trends suggest the outlook may turn sunny, plus financings updates on NuPathe, Euthymics Bioscience, Xoma and Immune Design Corp.
You may also be interested in...
A quarterly report shows an uptick in VC disbursements, but LP commitments are still lagging.
Fundraising successes by Trevena, Sunesis, Calithera and iPierian highlight the last two weeks' action.
New money is increasingly hard to come by for life sciences venture capital firms. Start-Up tracks VCs to determine which firms have older vintage funds and which have plenty of fresh capital to invest.